Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting Pyruvate Kinase M2 Phosphorylation Reverses Aggressive Cancer Phenotypes.

Cancer research - 15 Aug 2021

Apostolidi Maria, Vathiotis Ioannis A, Muthusamy Viswanathan, Gaule Patricia, Gassaway Brandon M, Rimm David L, Rinehart Jesse

Abstract excerpt

Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype with low survival rate and a lack of biomarkers and targeted treatments. Here, we target pyruvate kinase M2 (PKM2), a key metabolic component of oncogenesis. In patients with TNBC, PKM2pS37 was identified as a prominent phosphoprotein corresponding to the aggressive breast cancer phenotype that showed a characteristic nuclear...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Laminin
Share to MCF-7 Cells
Share to Pyridazines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pyridinium Compounds

Share to Pyrroles

Share to Pyruvate Kinase

Share to Thyroid Hormones

Share to Triple Negative Breast Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 34185676
DOI: 10.1158/0008-5472.CAN-20-4190
PMCID: PMC8373815

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting Pyruvate Kinase M2 Phosphorylation Reverses Aggressive Cancer Phenotypes.PMID 34185676Read ↗

Halicin Reduces the Warburg Effect and Overcomes Drug Resistance by Activating the Pyruvate Kinase M2 Pathway for Triple-Negative Breast Cancer TreatmentSemantic proximity Read ↗

Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibitionSemantic proximity Read ↗

Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth.Semantic proximity Read ↗

PKM2 modulates chemotherapy sensitivity by regulating autophagy and predicts the prognosis and immunity in pancancerSemantic proximity Read ↗

NONO directs PKM2-mediated H3T11ph to promote triple-negative breast cancer metastasis by activating SERPINE1 expressionSemantic proximity Read ↗

Overexpression of PKMYT1 associated with poor prognosis and immune infiltration may serve as a target in triple-negative breast cancerSemantic proximity Read ↗

NONO interacts with nuclear PKM2 and directs histone H3 phosphorylation to promote triple-negative breast cancer metastasisSemantic proximity Read ↗

Altered glycometabolism affects both clinical features and prognosis of triple-negative and neoadjuvant chemotherapy-treated breast cancer.Semantic proximity Read ↗

Expression of PGK1 in Breast Cancers Alters Their Sensitivity to Ferroptosis Induction via Metabolic ReprogrammingSemantic proximity Read ↗

Definition of PKC-α, CDK6, and MET as Therapeutic Targets in Triple-Negative Breast CancerSemantic proximity Read ↗

Discovery of a Novel Selective PAK1/HDAC6/HDAC10 Inhibitor ZMF-25 that Induces Mitochondrial Metabolic Breakdown and Autophagy-Related Cell Death in Triple-Negative Breast CancerSemantic proximity Read ↗

Protein kinase PIM2: A simple PIM family kinase with complex functions in cancer metabolism and therapeuticsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.